KMS Medisurgi reported a ₹24.55 lakh profit after tax (PAT) for FY26, down from ₹43.98 lakh in the previous year. The decline followed a 12.42% drop in revenue to ₹1,220.85 lakh, as the medical device manufacturer navigated softer sales volumes.

The Board of Directors recommended a final dividend of ₹0.05 (0.5%) per equity share for approval at the upcoming Annual General Meeting (AGM). The payout represents a continuation of the company’s dividend policy despite the contraction in earnings.

Financial Performance

Revenue from operations fell to ₹1,220.85 lakh in FY26 compared to ₹1,393.86 lakh in FY25. Total expenses decreased proportionally to ₹1,188.84 lakh from ₹1,335.71 lakh.

Cost of materials consumed stood at ₹882.19 lakh, down from ₹1,054.78 lakh. Employee benefit expenses rose to ₹130.45 lakh from ₹119.71 lakh, while depreciation increased significantly to ₹47.13 lakh from ₹26.57 lakh, reflecting recent capital expenditures.

Balance Sheet and Cash Flow

As of March 31, 2026, total assets stood at ₹1,054.80 lakh. Inventories remained stable at ₹253.80 lakh, while trade receivables declined sharply to ₹322.22 lakh from ₹424.11 lakh, indicating improved collection efficiency. Cash and cash equivalents nearly doubled to ₹110.47 lakh from ₹46.73 lakh.

Long-term borrowings decreased to ₹77.34 lakh from ₹91.28 lakh, primarily due to repayments of unsecured loans from directors and related parties. The debt-to-equity ratio improved to 0.09 from 0.11.

Auditor Qualifications

Statutory auditors H.H. Dedhia & Associates issued a qualified opinion on the financial statements. The qualification stems from two key issues:

• The company uses LIC group gratuity reports for post-employment benefits instead of an actuarial valuation, departing from AS-15.
• Quantitative stock records were only recently implemented for material items, preventing the auditors from commenting on stock movement and closing stock value of ₹253.80 lakh.

AGM Details

The 28th AGM is scheduled for September 30, 2026, at the registered office in Mumbai. Key agenda items include:

• Adoption of standalone financial statements for FY26.
• Approval of the final dividend of ₹0.05 per share.
• Reappointment of Mr. Rohan Devang Kanakia as a director retiring by rotation.

Remote e-voting will be available via KfinTech from September 27 to September 29, 2026. The register of members will remain closed from September 24 to September 30, 2026.

What the Numbers Show

The divergence between declining revenue and rising employee costs highlights margin pressure. While cost of materials fell in line with sales, employee benefit expenses grew by 9% despite lower turnover. Additionally, depreciation costs surged by 77% due to capital additions of ₹172.00 lakh in plant and machinery, suggesting the company is investing in capacity expansion even as current demand softens.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE870V01014/e86f75ea-c1c8-4565-8e4a-a94b38255bb0.pdf

KMS Medisurgi has scheduled a Board of Directors meeting for September 5, 2026. The gathering will focus on approving the financial statements for the fiscal year ended March 31, 2026.

The company informed the Bombay Stock Exchange about the upcoming session on August 27, 2026. This disclosure aligns with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Agenda Highlights

The board will transact several key items during the session. These include:

• Approving the Directors' Report for FY26
• Recommending the Financial Statements for member adoption
• Considering the Management Discussion and Analysis Report
• Deciding on the final dividend recommendation for equity shares
• Setting dates for the closure of the Register of Members and Share Transfer Books

Additionally, the board will appoint a Scrutinizer for the voting process at the 28th Annual General Meeting. The directors will also determine the day, date, time, and venue for convening this AGM.

Procedural Details

Siddharth Kanakia, Managing Director of KMS Medisurgi, signed the intimation letter. The company is headquartered in Mumbai. No financial figures were disclosed in this preliminary notice.